| 5.91 0.25 (4.42%) | 10-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.38  |
1-year : | 7.94 |
| Resists | First : | 6.32 |
Second : | 6.8 |
| Pivot price | 5.9 |
|||
| Supports | First : | 5.55 | Second : | 4.61 |
| MAs | MA(5) : | 5.76 |
MA(20) : | 6.04 |
| MA(100) : | 5.8 |
MA(250) : | 7.41 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 17 |
D(3) : | 15.8 |
| RSI | RSI(14): 46.1 |
|||
| 52-week | High : | 12.18 | Low : | 4.75 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VALN ] has closed above bottom band by 50.0%. Bollinger Bands are 12.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.92 - 5.94 | 5.94 - 5.96 |
| Low: | 5.78 - 5.81 | 5.81 - 5.83 |
| Close: | 5.87 - 5.91 | 5.91 - 5.95 |
Valneva SE operates as a specialized biopharmaceutical company, concentrating its efforts on developing and bringing to market preventative vaccines for infectious diseases where current medical options are insufficient. Its portfolio of commercial travel vaccines includes IXIARO, an inactivated vaccine derived from Vero cell culture, which provides active immunity against Japanese encephalitis. Another offering is DUKORAL, an oral vaccine designed to guard against diarrhea induced by Vibrio cholerae or enterotoxigenic Escherichia coli (ETEC) bacteria. The company's development pipeline features VLA2001, a candidate vaccine targeting SARS-CoV-2. Additionally, Valneva is progressing with VLA15, a Lyme disease vaccine candidate that has successfully concluded Phase II clinical trials and is being co-developed and commercialized with Pfizer, Inc. They are also advancing VLA1553, a chikungunya virus vaccine candidate currently undergoing Phase III clinical evaluation, in partnership with Instituto Butantan for its development, production, and marketing as a single-shot vaccine. Valneva's products are sold across a wide geographical area, including the United States, Canada, Germany, Austria, the Nordic countries, the United Kingdom, various other European nations, and internationally. Founded in 1998, the company maintains its headquarters in Saint-Herblain, France.
Thu, 15 Oct 2026
Valneva (VALN) expects decisions on its Pfizer-partnered Lyme vaccine candidate within 12 months - Stock Titan
Wed, 14 Oct 2026
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences - The Daily Tribune News
Wed, 14 Oct 2026
Full Transcript: Valneva Q2 2026 Earnings Call - Benzinga
Mon, 12 Oct 2026
Weekly Recap: UK authorization revoked and Brazil 61,000+ vaccinated - TradingView
Fri, 09 Oct 2026
Valneva (VALN) Short Interest & Short Float | Updated Oct 2026 - MarketBeat
Thu, 08 Oct 2026
A UK vaccine decision won't be appealed by Valneva (VALN), which expects minimal sales impact. - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 95 (M) |
| Shares Float | 86 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 3.9 (%) |
| Shares Short | 207 (K) |
| Shares Short P.Month | 194 (K) |
| EPS | -2.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.99 |
| Profit Margin | -110.3 % |
| Operating Margin | -75 % |
| Return on Assets (ttm) | -16.7 % |
| Return on Equity (ttm) | -117.9 % |
| Qtrly Rev. Growth | -27.8 % |
| Gross Profit (p.s.) | -0.63 |
| Sales Per Share | 1.5 |
| EBITDA (p.s.) | -1.05 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -56 (M) |
| Levered Free Cash Flow | -43 (M) |
| PE Ratio | -2.82 |
| PEG Ratio | 0 |
| Price to Book value | 5.96 |
| Price to Sales | 3.92 |
| Price to Cash Flow | -10.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|